Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 99-105

  Rini, Brian I ^a   Weinberg, Vivian ^a   Bok, Robert ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG EFFECT; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROSTATE TUMOR; STATISTICAL MODEL;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 0037208522     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.163     Document Type: Article

References (11)

1. Powell CR, Huisman TK, Riffenburgh RH, et al: Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol 157:1754-1759, 1997.
2. Moul JW, Connelly RR, Lubeck DP, et al: Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor Databases. J Urol 166:1322-1327, 2001.
3. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
4. Zagars GK, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997.
5. Nelson WG, Simons JW, Mikhak B, et al: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 46:S67-S72, 2000.
6. Simons JW, Mikhak B, Chang JF, et al: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160-5168, 1999.
7. Simons JW, Small EJ, Nelson W, et al: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Program/Proc Am Soc Clin Oncol 20, 2001 (abstr 1073).
8. Small EJ, Reese DM, Um B, et al: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5:1738-1744, 1999.
9. Dreicer R, See WA, Klein EA: Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19:261-265, 2001.
10. Wasilenko WJ, Palad AJ, Somers KD, et al: Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 68:259-264, 1996.
11. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999.